-
Organicell Regenerative Medicine ( OTC:OCEL ) has closed on an additional $1M private stock purchase at $0.04 per share and secured a $10M equity line of credit with Tysadco Partners.
-
Tysadco specializes in micro-cap funding and has completed several ELOC's ranging from $2M-30M over the last five years.
-
This capital raise brings the total amount of new funding deals to $16.5M.
-
Company has been approved by the FDA to conduct Phase I/II clinical trials on their investigational new drug Zofin.
For further details see:
Organicell Regenerative Medicine secures additional $11M financing for clinical trial enrollment